

*Curriculum Vitae M.C. Fantini***Personal and Contact information:**

Name: Massimo Claudio
 Surname: Fantini
 Age: 39
 Date and Place of birth: 07/07/1976, Johannesburg
 Republic of South Africa
 Address: Via Spinoza 10, 00137, Rome, Italy
 Phone (Office): +39(0)672596150
 Fax: +39(0)672596391
 Mobile: +393455727292
 Email: m.fantini@med.uniroma2.it

**Academic Background:**

- 2001 Undergraduate scholarship at the **University of Kiel (Germany)**, Christian Albrecht, MUCOSA laboratories (Prof.Dr. Stefan Schreiber)
- 2002 Degree in Medicine and Surgery at the University of Rome "Tor Vergata", Italy
 Final mark **110/110 cum laude**
 Dissertation on "Expression of NOD2 in epithelial cell lines HT-29 and HeLa"

Postgraduate works and positions:

- 2003-2005 Research fellow at the **University of Mainz (Germany)**, Johannes Gutenberg, at the Laboratories of Mucosal Immunology (Prof. Dr. Markus F. Neurath).
- 2005 PhD in "Experimental physiopathology: Mucosal Immunology" at the University of Rome "Tor Vergata", Department of Internal Medicine, Division of Gastroenterology (Coordinator Prof. Dr. Francesco Pallone). Dissertation on "*Role of TGF-beta in colitis and colitis associated colorectal cancer*"
- 2006-2009 Post-graduate school of Gastroenterology
- 2006-2009 PostDoc position at the University "Tor Vergata", Rome, Italy
- 2009-2013 Professorship at the University of Rome "Tor Vergata", research program "Rientro dei cervelli".
- 2013-2014 Researcher at the University "Tor Vergata", Rome, Italy
- 2015-present Associate Professor of Gastroenterology at the University "Tor Vergata", Rome, Italy
 Policlinico Tor Vergata - UOC di GASTROENTEROLOGIA ed ENDOSCOPIA DIGESTIVA - Viale Oxford n. 81, 00133 Roma (Prof. Monteleone).

Awards and granted projects:

-
- 2001 SIGE (Società Italiana di Gastroenterologia) research prize.
- 2005 30.000€ for one year granted by the “Forschungsförderungsprogramm MAIFOR 2005” for the project “Characterization and modulation of tumor induced regulatory T cells in melanoma and colorectal cancer”. Role: **Responsible of the fund and Principal Investigator.**
- 2008 *Rising Star in Gastroenterology* award, nominated by the ASNEMGE.
- 2009 150.000€ MFAG AIRC grant (Cod. 9363) for studying the “Role of Smad7 in the immune-modulation of inflammation-related colorectal cancer”. Role: **Responsible of the fund and Principal Investigator.**
- 2011 “Fondazione Aldo Torsoli per le le Malattie dell’Apparato digerente del Fegato e del Pancreas” award.
- 2012 900.000€ FIRB (Fondo per gli Investimenti della Ricerca di Base) grant for studying “New molecular and cellular mechanisms involved in colitis-associated colorectal cancer: implications for innovative therapeutic approaches”. Role: **Coordinator of the fund and Principal Investigator.**
- 2012 IG AIRC grant (Cod. 13304) for the study “T cell plasticity in colitis-associated colorectal cancer”, three years grant 54.000€ funded for the first year. Role: **Responsible of the fund and Principal Investigator.**

Academic teaching activity:

Didactic module “Il saper fare in Gastroenterologia” included in the Gastroenterology (MED12) discipline of the course of Medicine and Surgery.

Didactic module “Modelli sperimentali di infiammazione intestinale” as elective activity for students in Gastroenterology (MED12) discipline of the course of Medicine and Surgery.

Tutorial activity of undergraduate fellows in Gastroenterology (MED12).

Clinical activity:

Assistance and care of outpatients and inpatients affected by gastroenterological diseases with a specific expertise in the care of inflammatory bowel disease patients. The activity is divided between the outpatient ward, inpatient ward and the endoscopy unit at the “Fondazione PTV”, Roma. I am personally involved in the screening of long lasting colitis and I am familiar with magnification and contrast-enhancement endoscopic techniques used for this purpose.

Scientific activity, publications:

The products of my research activity have been published in: Nature Clinical Practice in Gastroenterology and Hepatology, Molecular Cancer Therapy, Molecular Therapy, Journal of Experimental Medicine, Carcinogenesis, Cancer Research, World Journal of Gastroenterology, Blood, Immunity, Gastroenterology, Gut, Alimentary Pharmacology & Therapeutics, The Journal of Immunology, Journal of Biological Chemistry, Cell Cycle, Biology of Reproduction, European Journal of Immunology, Infection Immunology, Inflammatory Bowel Disease, Current Drug Targets, Nature Protocols, Expert Review in Anticancer Therapy.

Total impact factor of the published papers: 318,295; *h-Index*: 24

Editorial activity:

Reviewer for journals (*selected*): Gut, Mucosal Immunology, The Journal of Immunology, The European Journal of Immunology, Gastroenterology.

Reviewer for research funding agencies: The Irish research government organization.

Editorial board membership: Member for the editorial board of Digestive and Liver Disease.

Field of interests:**Clinical research:**

-
- 1) Co-Investigator in the phase I clinical trial on safety and tolerability of the Smad7 oligoantisense GED301 in IBD patients (completed).
 - 2) Co-investigator in the phase II randomized controlled trial of the Smad7 oligoantisense GED301 in IBD patients.

Basic science research and achievements:

- 1) Mechanisms of mucosal immuno-regulation in human inflammatory bowel disease:
 - a. Study of TGF-beta in the immuno-regulation of the gut mucosal immune system.
 - b. Description of the role played by TGF-beta in the peripheral induction of CD4+CD25+FoxP3+ regulatory T cells from a population of naive cells.
 - c. Characterization of the suppressive effect of TGF-beta induced regulatory cells in Th1 mediated colitis.
 - d. Study of the *in vivo* relevance of the peripheral induction of regulatory cells by TGF-beta.
 - e. Study of the mechanisms modulating the induction and regulatory function of TGF-beta induced regulatory cells.
 - f. Identification of TGF-beta dependent counter regulatory systems different from the induction of regulatory cells.
- 2) Regulation of the mucosal immune response by colorectal cancer
 - a. Study of the TGF-beta dependent mechanisms involved in the immune response evoked by primary and metastatic colorectal cancer.
 - b. Description of the role of *IL-6 transsignalling* in colorectal cancer
 - c. Study of the role played by TGF-beta induced regulatory cells in the phenomenon of immunosurveillance evasion.
 - d. Study of the tumor derived TGF-beta effects in the modulation of the immune system during the process of metastatization.
 - e. Study of the role of T cell-specific Smad7 expression in colitis-associated colorectal cancer.

Memberships:

-
- Italian Group for the Intestinal Bowel Disease (**IG-IBD**): Member of the scientific committee.
 - Società Italiana di Gastroenterologia ed Epatologia (**SIGE**): Member.
 - European Crohn's and Colitis Organization (**ECCO**): Member.

Latest participation to international meetings:

- Invited lecture at the British Society of Immunology (BSI) congress 2011. Title of the talk "*Smad7, gutinflammation and cancer*".
- Oral communication at the Digestive Disease Week 2009. Title of the talk "*Smad7 expression in T cells prevents colitis-associated colorectal cancer.*"
- Oral communication at the Digestive Disease Week 2008. Title of the talk "*T Cell-Specific Smad7 Over-Expression Reduces Regulatory T Cell-Mediated Control of Colitis.*"
- Oral communication at the Digestive Disease Week 2007. Title of the talk "*Trans-signaling via the soluble IL-6R suppresses oral tolerance by blocking the induction of FoxP3 in naive CD4+CD25- T cells*".
- Abstract selected for poster presentation at Digestive Diseases Week 2007 with the title: "*IL-21 selectively prevents TGF-beta induced regulatory T cells*".

Publications:

1. MA RUSSO, ML GIUSTIZIERI, A FAVALE, **M FANTINI**, L CAMPAGNOLO, D KONDA, F GERMANO, D FARINI, C MANNA, G SIRACUSA. Spatiotemporal patterns of expression of neurotrophins and neurotrophin receptors in mice suggest functional roles in testicular and epididymal morphogenesis. *BIOLOGY OF REPRODUCTION* 1999.
2. L BIANCONE, C TOSTI, D FINA, **M FANTINI**, F DE NIGRIS, A GEREMIA, F PALLONE. Review article: maintenance treatment of Crohn's disease. *ALIMENTARY PHARMACOLOGY & THERAPEUTICS* 2003.
3. L BIANCONE, C TOSTI, F DE NIGRIS, **M FANTINI**, F PALLONE. Selective cyclooxygenase-2 inhibitors and relapse of inflammatory bowel disease. *GASTROENTEROLOGY* 2003.
4. L BIANCONE, **M FANTINI**, C TOSTI, R BOZZI, P VAVASSORI, F PALLONE. Fecal alpha 1-antitrypsin clearance as a marker of clinical relapse in patients with Crohn's disease of the distal ileum. *EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY* 2003.
5. P ROSENSTIEL, **M FANTINI**, K BRUTIGAM, T KHBACHER, GH WAETZIG, D SEEGERT, S SCHREIBER. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. *GASTROENTEROLOGY* 2003.
6. C BECKER, **M FANTINI**, C SCHRAMM, HA LEHR, S WIRTZ, A NIKOLAEV, J BURG, S STRAND, R KIESSLICH, S HUBER, H ITO, N NISHIMOTO, K YOSHIZAKI, T KISHIMOTO, PR GALLE, M BLESSING, S ROSE-JOHN, MF NEURATH. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. *IMMUNITY* 2004.
7. **M FANTINI**, C BECKER, G MONTELEONE, F PALLONE, PR GALLE, MF NEURATH. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. *JOURNAL OF IMMUNOLOGY* 2004.
8. G MONTELEONE, J MANN, I MONTELEONE, P VAVASSORI, R BREMNER, **M FANTINI**, G DEL VECCHIO BLANCO, R TERSIGNI, L ALESSANDRONI, D MANN, F PALLONE, TT MACDONALD. A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. *THE JOURNAL OF BIOLOGICAL CHEMISTRY* 2004.
9. C BECKER, **M FANTINI**, S WIRTZ, A NIKOLAEV, HA LEHR, PR GALLE, S ROSE-JOHN, MF NEURATH. IL-6 signaling promotes tumor growth in colorectal cancer. *CELL CYCLE* 2005.
10. C BECKER, **M FANTINI**, S WIRTZ, A NIKOLAEV, R KIESSLICH, HA LEHR, PR GALLE, MF NEURATH. In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy. *GUT* 2005.

11. **M FANTINI** , C BECKER, MF NEURATH. Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy. EXPERT REVIEW OF ANTICANCER THERAPY 2005.
12. S WIRTZ, C BECKER, **M FANTINI** , EE NIEUWENHUIS, I TUBBE, PR GALLE, HJ SCHILD, M BIRKENBACH, RS BLUMBERG, MF NEURATH. EBV-induced gene 3 transcription is induced by TLR signaling in primary dendritic cells via NF-kappa B activation. JOURNAL OF IMMUNOLOGY 2005.
13. C BECKER, **M FANTINI** , MF NEURATH. TGF-beta as a T cell regulator in colitis and colon cancer. CYTOKINE & GROWTH FACTOR REVIEWS 2006.
14. C BECKER, H DORNHOFF, C NEUFERT, **M FANTINI** , S WIRTZ, S HUEBNER, A NIKOLAEV, HA LEHR, AJ MURPHY, DM VALENZUELA, GD YANCOPOULOS, PR GALLE, M KAROW, MF NEURATH. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. JOURNAL OF IMMUNOLOGY 2006.
15. **M FANTINI** , C BECKER, I TUBBE, A NIKOLAEV, HA LEHR, P GALLE, MF NEURATH. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. GUT 2006.
16. **M FANTINI** , C BECKER, R KIESSLICH, MF NEURATH. Drug insight: novel small molecules and drugs for immunosuppression. NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY 2006.
17. G MONTELEONE, R CARUSO, D FINA, I PELUSO, V GIOIA, C STOLFI, **M FANTINI** , F CAPRIOLI, R TERSIGNI, L ALESSANDRONI, TT MACDONALD, F PALLONE. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. GUT 2006.
18. C BECKER, **M FANTINI** , MF NEURATH. High resolution colonoscopy in live mice. NATURE PROTOCOLS 2007.
19. C NEUFERT, C BECKER, S WIRTZ, **M FANTINI** , B WEIGMANN, PR GALLE, MF NEURATH. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. EUROPEAN JOURNAL OF IMMUNOLOGY 2007.
20. D FINA, **M FANTINI** , F PALLONE, G MONTELEONE. Role of interleukin-21 in inflammation and allergy. INFLAMMATION & ALLERGY - DRUG TARGETS 2007.
21. **M FANTINI** , A RIZZO, D FINA, R CARUSO, C BECKER, MF NEURATH, TT MACDONALD, F PALLONE, G MONTELEONE. IL-21 regulates experimental colitis by modulating the balance between T(reg) and Th17 cells. EUROPEAN JOURNAL OF IMMUNOLOGY 2007.
22. **M FANTINI** , G MONTELEONE, TT MACDONALD. New players in the cytokine orchestra of inflammatory bowel disease. INFLAMMATORY BOWEL DISEASES 2007.
23. **M FANTINI** , S DOMINITZKI, A RIZZO, MF NEURATH, C BECKER. In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells. NATURE PROTOCOLS 2007.
24. I PELUSO, D FINA, R CARUSO, C STOLFI, F CAPRIOLI, **M FANTINI** , G CASPANI, E GROSSI, L DI IORIO, FM PAONE, F PALLONE, G MONTELEONE. Lactobacillus paracasei subsp. paracasei B21060 suppresses human T-cell proliferation. INFECTION AND IMMUNITY 2007.
25. I PELUSO, **M FANTINI** , D FINA, R CARUSO, M BOIRIVANT, TT MACDONALD, F PALLONE, G MONTELEONE. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. JOURNAL OF IMMUNOLOGY 2007.
26. R CARUSO, D FINA, I PELUSO, C STOLFI, **M FANTINI** , V GIOIA, F CAPRIOLI, G DEL VECCHIO BLANCO, OA PAOLUZI, TT MACDONALD, F PALLONE, G MONTELEONE. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. JOURNAL OF IMMUNOLOGY 2007.
27. R CARUSO, D FINA, I PELUSO, **M FANTINI** , C TOSTI, G DEL VECCHIO BLANCO, OA PAOLUZI, F CAPRIOLI, F ANDREI, C STOLFI, M ROMANO, V RICCI, TT MACDONALD, F PALLONE, G MONTELEONE.

IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. JOURNAL OF IMMUNOLOGY 2007.

28. S DOMINITZKI, **M FANTINI** , C NEUFERT, A NIKOLAEV, PR GALLE, J SCHELLER, G MONTELEONE, S ROSE-JOHN, MF NEURATH, C BECKER. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. JOURNAL OF IMMUNOLOGY 2007.

29. C STOLFI, D FINA, R CARUSO, F CAPRIOLI, **M FANTINI** , A RIZZO, M SARRA, F PALLONE, G MONTELEONE. Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. CARCINOGENESIS 2008;29:1258-1266.

30. C STOLFI, D FINA, R CARUSO, F CAPRIOLI, M SARRA, **M FANTINI** , A RIZZO, F PALLONE, G MONTELEONE. Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. BIOCHEMICAL PHARMACOLOGY 2008;75:668-676.

31. D FINA, M SARRA, **M FANTINI** , A RIZZO, R CARUSO, F CAPRIOLI, C STOLFI, I CARDOLINI, M DOTTORI, M BOIRIVANT, F PALLONE, TT MACDONALD, G MONTELEONE. Regulation of gut inflammation and th17 cell response by interleukin-21. GASTROENTEROLOGY 2008;134:1038-1048.

32. **M FANTINI** , F PALLONE. Cytokines: from gut inflammation to colorectal cancer. CURRENT DRUG TARGETS 2008;9:375-380.

33. **M FANTINI** , G MONTELEONE, TT MACDONALD. IL-21 comes of age as a regulator of effector T cells in the gut. MUCOSAL IMMUNOLOGY UPDATE 2008;1:110-115.

34. R CARUSO, D FINA, OA PAOLUZI, G DEL VECCHIO BLANCO, C STOLFI, A RIZZO, F CAPRIOLI, M SARRA, F ANDREI, M FANTINI , TT MACDONALD, F PALLONE, G MONTELEONE. IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. EUROPEAN JOURNAL OF IMMUNOLOGY 2008;38:470-478.

35. S VETRANO, M RESCIGNO, MR CERA, C CORREALE, C RUMIO, A DONI, **M FANTINI** , A STURM, E BORRONI, A REPICI, M LOCATI, A MALESCI, E DEJANA, S DANESE. Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. GASTROENTEROLOGY 2008.

36. **M FANTINI** , A RIZZO, D FINA, R CARUSO, M SARRA, C STOLFI, C BECKER, TT MACDONALD, F PALLONE, MF NEURATH, G MONTELEONE. Smad7 Controls Resistance of Colitogenic T Cells to Regulatory T Cell-Mediated Suppression. GASTROENTEROLOGY 2009.

37. **M FANTINI** , F Pallone, G Monteleone. Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies. WORLD JOURNAL OF GASTROENTEROLOGY 2009.

38. R CARUSO, C STOLFI, M SARRA, A RIZZO, **M FANTINI** , F PALLONE, TT MACDONALD, G MONTELEONE. Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via a p38 Map kinase-dependent induction of SOCS-3. ANIMAL BLOOD GROUPS AND BIOCHEMICAL GENETICS 2009.

39. R CARUSO, M SARRA, C STOLFI, A RIZZO, D FINA, **M FANTINI** , F PALLONE, TT MACDONALD, G MONTELEONE. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. GASTROENTEROLOGY 2009.

40. S VETRANO, EM BORRONI, A SARUKHAN, B SAVINO, R BONECCHI, C CORREALE, V ARENA, **M FANTINI** , M RONCALLI, A MALESCI, A MANTOVANI, M LOCATI, S DANESE. The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6. GUT 2009.

41. C STOLFI, M SARRA, R CARUSO, **M FANTINI** , D FINA, R PELLEGRINI, G PALMIERI, T MACDONALD T., F PALLONE, G MONTELEONE. Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine. GASTROENTEROLOGY 2010.

42. M SARRA, I MONTELEONE, C STOLFI, **M FANTINI** , P SILERI, G SICA, R TERSIGNI, TT MACDONALD, F PALLONE, G MONTELEONE. Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. INFLAMMATORY BOWEL DISEASES 2010.
43. A RIZZO, F PALLONE, G MONTELEONE, **M FANTINI** . Intestinal inflammation and colorectal cancer: a double-edged sword? WORLD JOURNAL OF GASTROENTEROLOGY 2011.
44. A RIZZO, I MONTELEONE, D FINA, C STOLFI, R CARUSO, **M FANTINI** , E FRANZE, R SCHWENDENER, F PALLONE, G MONTELEONE. Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages. INFLAMMATORY BOWEL DISEASES 2011.
45. A RIZZO, MJ WALDNER, C STOLFI, M SARRA, D FINA, C BECKER, MF NEURATH, TT MACDONALD, F PALLONE, G MONTELEONE, **M FANTINI** . Smad7 expression in T cells prevents colitis-associated cancer. CANCER RESEARCH 2011.
46. C STOLFI, A RIZZO, E FRANZE, A ROTONDI, **M FANTINI** , M SARRA, R CARUSO, I MONTELEONE, P SILERI, L FRANCESCHILLI, F CAPRIOLI, S FERRERO, T MACDONALD T., F PALLONE, G MONTELEONE. Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. JOURNAL OF EXPERIMENTAL MEDICINE 2011.
47. C STOLFI, R CARUSO, E FRANZE, A RIZZO, A ROTONDI, I MONTELEONE, **M FANTINI** , F PALLONE, G MONTELEONE. 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression. MOLECULAR CANCER THERAPEUTICS 2011.
48. TT MACDONALD, I MONTELEONE, **M FANTINI** , G MONTELEONE. Regulation of homeostasis and inflammation in the intestine. GASTROENTEROLOGY 2011.
49. F ZORZI, E CALABRESE, I MONTELEONE, **M FANTINI** , S ONALI, L BIANCONE, F PALLONE, G MONTELEONE. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease. ALIMENTARY PHARMACOLOGY & THERAPEUTICS 2012.
50. G MONTELEONE, **M FANTINI** , S ONALI, F ZORZI, G SANCESARIO, S BERNARDINI, E CALABRESE, F VITI, I MONTELEONE, L BIANCONE, F, PALLONE. Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn's Disease. MOLECULAR THERAPY 2012.
51. G MONTELEONE, **M FANTINI** , S ONALI, F ZORZI, G SANCESARIO, S BERNARDINI, E CALABRESE, F VITI, I MONTELEONE, L BIANCONE, F PALLONE. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. MOLECULAR THERAPY 2012.
52. TT MACDONALD, A VOSSENKAEMPER, **M FANTINI** , G MONTELEONE. Reprogramming the immune system in IBD. DIGESTIVE DISEASES 2012.
53. A DI SABATINO, A MOSCHETTA, D CONTE, C TIRIBELLI, GASTROENTEROLOGY TRANSLATIONAL COMMITTEE OF THE ITALIAN SOCIETY OF, FA CAPRIOLI, L FABRIS, **M FANTINI** , L FRULLONI, G MONTELEONE, M ROMANO, G SARNELLI, GS. BARONI. The impact of translational research on gastroenterology. DIGESTIVE AND LIVER DISEASE 2014.
54. A RIZZO, V DE MARE, C ROCCHI, C STOLFI, A COLANTONI, M NEURATH, T MACDONALD, F PALLONE, G MONTELEONE, **M FANTINI** . Smad7 induces plasticity in tumor-infiltrating Th17 cells and enables TNF-alpha-mediated killing of colorectal cancer cells. CARCINOGENESIS 2014;35:1536-1546.
55. A RIZZO, V DE MARE, C ROCCHI, C STOLFI, A COLANTONI, MF NEURATH, TT MACDONALD, F PALLONE, G MONTELEONE, **M FANTINI** . Smad7 induces plasticity in tumor-infiltrating Th17 cells and enables TNF-alpha-mediated killing of colorectal cancer cells. CARCINOGENESIS 2014.

56. C STOLFI, V DE SIMONE, A COLANTONI, E FRANZÈ, E RIBICHINI, **M FANTINI** , R CARUSO, I MONTELEONE, GS SICA, P SILERI, TT MACDONALD, F PALLONE, G. MONTELEONE. A functional role for Smad7 in sustaining colon cancer cell growth and survival. CELL DEATH & DISEASE 2014.
57. V DE SIMONE, E FRANZÈ, G RONCHETTI, A COLANTONI, **M FANTINI** , D DI FUSCO, GS SICA, P SILERI, TT MACDONALD, F PALLONE, G MONTELEONE, C. STOLFI. Th17-type cytokines, IL-6 and TNF- α synergistically activate STAT3 and NF- κ B to promote colorectal cancer cell growth. ONCOGENE 2014.
58. G MONTELEONE, MF NEURATH, S ARDIZZONE, A DI SABATINO, **M FANTINI** , F CASTIGLIONE, ML SCRIBANO, A ARMUZZI, F CAPRIOLI, GC STURNIOLO, F ROGAI, M VECCHI, R ATREYA, F BOSSA, S ONALI, M FICHERA, GR CORAZZA, L BIANCONE, V SAVARINO, R PICA, A ORLANDO, F. PALLONE. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. NEW ENGLAND JOURNAL OF MEDICINE 2015.
59. V DE SIMONE, G RONCHETTI, E FRANZÈ, A COLANTONI, A ORTENZI, **M FANTINI** , A RIZZO, GS SICA, P SILERI, P ROSSI, TT MACDONALD, F PALLONE, G MONTELEONE, C. STOLFI. Interleukin-21 sustains inflammatory signals that contribute to sporadic colon tumorigenesis. ONCOTARGET 2015.

Rome 31 March 2016

Massimo C Fantini

